Latest News

Under the US agreement, OPUVIZ (aflibercept-yszy), a biosimilar to Eylea (aflibercept) 2 mg, may launch in January 2027.

Inder Paul Singh, MD, spoke alongside Mary Qiu, MD, and Danica J. Marrelli, OD, FAAO, AAODip, in a CE Spotlight Symposium at the conference.

Clear counseling and tailored lens choice reduce postoperative dissatisfaction

Explore latest RVO care: faricimab, Eylea HD, and biosimilars that cut injection burden and protect vision from macular edema.

FDA clears DifGen’s generic fluorometholone 0.1% eye drop suspension, expanding lower-cost options for anterior eye inflammation and steroid care.

Phase 1b data show KSI-101 rapidly clears inflammatory macular edema, delivers long-lasting fluid control without steroids, and advances into enrolling phase 3 trials.

A closer look at the science powering next-generation retinal treatments

Reduced tobacco use and access to care are key components

Zarmeena Vendal, MD, discussed the intersections between cataract surgery and glaucoma.

Inder Paul Singh, MD, discusses his practice's approach to office-based surgery.

McCabe, MD, presented alongside P. Dee Stephenson, MD, FACS, for the product theater titled "Know Your Dry Eye: Navigating the Challenges of Real-World Dry Eye Cases."